Olverembatinib demonstrated activity in patients with CP-CML who received first- or second-generation TKIs as first-line therapy.

Karnataka: Shilpa Medicare has received the Good Manufacturing Practice (GMP) Certification after the successful closure of ...

The FDA has granted approval for the use of encorafenib in combination with cetuximab and mFOLFOX6 for the treatment of ...

在市场信心的显著表现下，Inhibikase Therapeutics ...

Goldman Sachs’ asset arm is in the process of acquiring the Dutch pharmaceutical company Synthon International for 2 billion ...

Tyrosine kinase inhibitors (TKIs) are a class of targeted cancer therapies designed to block the action of tyrosine kinases, enzymes that play a key role in cellular functions such as growth, division ...

Updated 96-week data from the ASC4FIRST trial show asciminib significantly outperforms standard TKIs in major molecular ...

Longer-term data for Novartis Scemblix reinforce superior efficacy with favourable safety and tolerability profile in adults with newly diagnosed CML: Basel Tuesday, December 10, ...

(IN BRIEF) Novartis has announced promising 96-week results from the Phase III ASC4FIRST trial, showcasing Scemblix® (asciminib) as a superior treatment for newly diagnosed Philadelphia ...

(IN BRIEF) Novartis has announced promising 96-week results from the Phase III ASC4FIRST trial, showcasing Scemblix® (asciminib) as a superior treatment for newly diagnosed Philadelphia ...

Novartis (NVS) announced “positive,” longer-term results from the pivotal Phase 3 ASC4FIRST trial with Scemblix showing superior major molecular ...

Scemblix demonstrated sustained superior major molecular response (MMR) vs. all investigator-selected TKIs (74.1% vs. 52%) and vs. imatinib alone (76.2% vs. 47.1%), meeting both ASC4FIRST 96-week key ...